These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26940988)

  • 41. A post hoc analysis of d-threo-methylphenidate hydrochloride (focalin) versus d,l-threo-methylphenidate hydrochloride (ritalin).
    Weiss M; Wasdell M; Patin J
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1415-21. PubMed ID: 15502601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
    Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.
    Teicher MH; Polcari A; Foley M; Valente E; McGreenery CE; Chang WW; McKay G; Midha KK
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):416-31. PubMed ID: 16958567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.
    Schachar RJ; Tannock R; Cunningham C; Corkum PV
    J Am Acad Child Adolesc Psychiatry; 1997 Jun; 36(6):754-63. PubMed ID: 9183129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Attention-Deficit/Hyperactivity Disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints.
    Rapport MD; Randall R; Moffitt C
    J Atten Disord; 2002 Jun; 6(1):15-24. PubMed ID: 12045757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
    Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attention Deficit Hyperactivity Disorder Symptoms are Common in Patients in Opioid Maintenance Treatment.
    Fiksdal Abel K; Ravndal E; Clausen T; Bramness JG
    Eur Addict Res; 2017; 23(6):298-305. PubMed ID: 29320768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.
    Dürsteler KM; Berger EM; Strasser J; Caflisch C; Mutschler J; Herdener M; Vogel M
    Subst Abuse Rehabil; 2015; 6():61-74. PubMed ID: 26124696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction between methylphenidate, methadone and different antidepressant drugs on antinociception in mice, and possible clinical implications.
    Schreiber S; Bader M; Rubovitch V; Pick CG
    World J Biol Psychiatry; 2017 Jun; 18(4):300-307. PubMed ID: 26529542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.
    Levin FR; Bisaga A; Raby W; Aharonovich E; Rubin E; Mariani J; Brooks DJ; Garawi F; Nunes EV
    J Subst Abuse Treat; 2008 Jan; 34(1):80-9. PubMed ID: 17574796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse.
    Zhu J; Spencer TJ; Liu-Chen LY; Biederman J; Bhide PG
    Neuropharmacology; 2011; 61(1-2):283-92. PubMed ID: 21545805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between Adult Attention Deficit/Hyperactivity Disorder and Intravenous Misuse of Opioid and Benzodiazepine in Patients under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
    Lugoboni F; Zamboni L; Mantovani E; Cibin M; Tamburin S;
    Eur Addict Res; 2020; 26(4-5):263-273. PubMed ID: 31995807
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral Methylphenidate Treatment of an Adolescent ADHD Rat Model Does Not Alter Cocaine-Conditioned Place Preference during Adulthood: A Negative Report.
    Zhang-James Y; Lloyd DR; James ML; Yang L; Richards JB; Faraone SV
    J Psychiatr Brain Sci; 2019; 4():. PubMed ID: 31930173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.